AU3569995A - Muramyl peptide compositions for inhibiting hiv replication - Google Patents

Muramyl peptide compositions for inhibiting hiv replication

Info

Publication number
AU3569995A
AU3569995A AU35699/95A AU3569995A AU3569995A AU 3569995 A AU3569995 A AU 3569995A AU 35699/95 A AU35699/95 A AU 35699/95A AU 3569995 A AU3569995 A AU 3569995A AU 3569995 A AU3569995 A AU 3569995A
Authority
AU
Australia
Prior art keywords
inhibiting hiv
hiv replication
peptide compositions
muramyl peptide
replication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU35699/95A
Inventor
Georges Bahr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vacsyn SA
Original Assignee
Vacsyn SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vacsyn SA filed Critical Vacsyn SA
Publication of AU3569995A publication Critical patent/AU3569995A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

The use of non-toxic muramyl peptides, particularly Murabutide and Murametide, to prepare drugs for inhibiting HIV replication in humans is disclosed. Said muramyl peptides are capable of up to 100 % inhibition of retroviral replication in primary host monocyte cultures.
AU35699/95A 1994-09-26 1995-09-26 Muramyl peptide compositions for inhibiting hiv replication Abandoned AU3569995A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9411460A FR2724845B1 (en) 1994-09-26 1994-09-26 MURAMYL PEPTIDES COMPOSITIONS CAPABLE OF INHIBITING UP TO 100% REPLICATION OF AN ACQUIRED IMMUNO DEFICIENCY VIRUS, SUCH AS HIV
FR9411460 1994-09-26
PCT/FR1995/001239 WO1996009837A1 (en) 1994-09-26 1995-09-26 Muramyl peptide compositions for inhibiting hiv replication

Publications (1)

Publication Number Publication Date
AU3569995A true AU3569995A (en) 1996-04-19

Family

ID=9467271

Family Applications (1)

Application Number Title Priority Date Filing Date
AU35699/95A Abandoned AU3569995A (en) 1994-09-26 1995-09-26 Muramyl peptide compositions for inhibiting hiv replication

Country Status (11)

Country Link
EP (1) EP0783319B1 (en)
JP (1) JPH10506120A (en)
AT (1) ATE240114T1 (en)
AU (1) AU3569995A (en)
CA (1) CA2200993A1 (en)
DE (1) DE69530779T2 (en)
DK (1) DK0783319T3 (en)
ES (1) ES2197923T3 (en)
FR (1) FR2724845B1 (en)
PT (1) PT783319E (en)
WO (1) WO1996009837A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3006697A (en) * 1996-05-10 1997-12-05 Endorex Corporation Lipophile derivatives of muramylpeptides for treatment of retroviral infection and induction of chemokines
FR2809106A1 (en) * 2000-05-17 2001-11-23 Istac New human Ro/SSA-like polypeptide, useful for treatment, prevention and diagnosis of e.g. autoimmune disease and viral infection, also related nucleic acid and antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692148B3 (en) * 1992-06-12 1994-08-19 Vacsyn France Sa Adjuvant composition of humoral and cell-mediated immunity which does not induce a response vis-à-vis auto-antigenic determinants.

Also Published As

Publication number Publication date
PT783319E (en) 2003-09-30
ATE240114T1 (en) 2003-05-15
FR2724845A1 (en) 1996-03-29
WO1996009837A1 (en) 1996-04-04
DK0783319T3 (en) 2003-09-15
JPH10506120A (en) 1998-06-16
CA2200993A1 (en) 1996-04-04
ES2197923T3 (en) 2004-01-16
EP0783319B1 (en) 2003-05-14
DE69530779T2 (en) 2004-03-25
DE69530779D1 (en) 2003-06-18
EP0783319A1 (en) 1997-07-16
FR2724845B1 (en) 1997-01-17

Similar Documents

Publication Publication Date Title
ATE177757T1 (en) IMPROVED IMMUNOGENIC COMPOSITION AGAINST HUMAN GASTRIN 17
AU693747B2 (en) Imidazo(4,5-c)pyridin-4-amines
EP1210941A3 (en) Pharmaceutical compositions containing ritonavir (ABT-538) in combination with indinavir (MK-639) and their use for treating AIDS
AU2613995A (en) Lactobacillus strains of human origin, their compositions and uses thereof
IT1287967B1 (en) PHARMACEUTICAL PREPARATIONS FOR LOCAL ANESTHETIC USE
HUP9901186A2 (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
AU5861799A (en) Use of acetylcholinesterase inhibitors for the preparation of pharmaceutical compositions for the treatment of functional and/or organic pain syndromes
DE69725860D1 (en) PLAN FOR ADMINISTRATION OF H +, K + -ATPase INHIBITORS
BG102362A (en) New derivatives of amino acids, their preparation and application
RS49599B (en) Use of h+, k+ -atpaze inhibitors and glucocortifoids and pharmaceutical formulation
ES2131528T3 (en) NEW POLYPEPTIDES AND THEIR USE.
DK0633763T3 (en) Cosmetic or pharmaceutical compositions containing deacylated glycerophospholipids for topical use
AU1031697A (en) Novel geranylgeranyl-derivatives, process for the preparation thereof and related pharmaceutical compositions
MY104909A (en) Peptide compounds.
AU6633596A (en) Improved therapeutic agents
AU579593B2 (en) Novel peptides which are active on the central nervous system and have an action on the cholinergic system
AU3569995A (en) Muramyl peptide compositions for inhibiting hiv replication
MX9307203A (en) STEROIDAL COMPOUNDS OF ACIL-3-CARBOXI-3,5-DIENO-17Ó AND 17ß-SUBSTITUTED.
TR199700735T1 (en) Concomitant therapy for HIV infection with the use of the reverse transcriptase inhibitor 3T and the HIV protease inhibitor indinavir, optionally with azt, DD1 or DDC.
WO2004110470A3 (en) Use of collagen peptides to inhibit infection
WO1994021273A3 (en) USE OF ANGIOGENINE, AND/OR α1-MICROGLOBULINE AND/OR COMPLEMENTARY FACTOR D FOR LIMITING PROTEIN SECRETION
MX9800891A (en) Mocarhagin, a cobra venom protease, and therapeutic uses thereof.
MX9100974A (en) HYBRID FIBRINOLYTIC ENZYME AND PROCEDURE FOR ITS PREPARATION.
KR960033467A (en) Mucin secretion inhibitors